Oncolytics Biotech Inc. (ONCY) Income Statement
ONCY 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsONCY revenue and net income
ONCY growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ONCY quarterly EPS vs estimates
Oncolytics Biotech beat the analyst EPS estimate in 1 of the last 3 quarters. Next report: November 11, 2026 (estimate $-0.06).
ONCY income statement
| 2025 | |
|---|---|
| Revenue | $0 |
| Cost of revenue | $70,000 |
| Gross profit | −$70,000 |
| Research & development | $13.3M |
| Sales, general & admin | $15.4M |
| Total operating expenses | $28.7M |
| Operating income | −$28.7M |
| Interest income | $386,000 |
| Income before taxes | −$28.7M |
| Income taxes | $79,000 |
| Net income | −$28.8M |
| EBITDA | −$28.7M |
| EPS (diluted) | −$0.29 |
| Jun '26 | Mar '26 | Dec '25 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of revenue | — | $22,313 | — |
| Gross profit | — | −$22,313 | — |
| Research & development | $4.3M | $4.6M | $3.0M |
| Sales, general & admin | $5.1M | $4.7M | $6.9M |
| Total operating expenses | $9.4M | $9.3M | $9.7M |
| Operating income | −$9.4M | −$9.3M | −$9.7M |
| Interest income | $37,000 | $44,000 | $151,044 |
| Income before taxes | −$9.3M | −$9.2M | −$9.0M |
| Income taxes | $101,000 | — | $198,992 |
| Net income | −$9.4M | −$9.2M | −$9.2M |
| EBITDA | −$9.3M | −$9.3M | −$9.7M |
| EPS (diluted) | −$0.08 | −$0.11 | $0.00 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ONCY's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ONCY financial results
Oncolytics Biotech reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $28.8 million. Diluted earnings per share came to −$0.29.
See the ONCY stock overview for the latest quote and news, or the ONCY chart for price history and technical indicators.
ONCY income statement FAQ
Does Oncolytics Biotech have revenue?
Oncolytics Biotech reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Oncolytics Biotech profitable?
No. Oncolytics Biotech reported a net loss of $28.8 million in fiscal 2025.
How much does Oncolytics Biotech spend on research and development?
Oncolytics Biotech spent $13.3 million on research and development in fiscal 2025.
What are Oncolytics Biotech's earnings per share?
Oncolytics Biotech earned $-0.29 per diluted share in fiscal 2025.
When will Oncolytics Biotech report its next earnings?
Oncolytics Biotech is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Oncolytics Biotech's fiscal year end?
Oncolytics Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.